Michael C. Donegan - 06 Dec 2022 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Role: Interim CFO/CAO/VP of Finance
Signature: /s/ Michael C. Donegan
Issuer symbol: TXMD
Transactions as of: 06 Dec 2022
Net transactions value: -$4,345
Form type: 4
Filing time: 09 Dec 2022, 18:37:34 UTC
Previous filing: 31 Mar 2022
Next filing: 25 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TXMD	Common Stock	Options Exercise	$0	+2,300	+116%	$0.000000	4,288	06 Dec 2022	Direct	F1
transaction	TXMD	Common Stock	Options Exercise	$0	+380	+8.9%	$0.000000	4,668	06 Dec 2022	Direct	F1
transaction	TXMD	Common Stock	Options Exercise	$0	+534	+11%	$0.000000	5,202	06 Dec 2022	Direct	F1
transaction	TXMD	Common Stock	Options Exercise	$0	+262	+5%	$0.000000	5,464	06 Dec 2022	Direct	F1
transaction	TXMD	Common Stock	Sale	$4,345	-910	-17%	$4.78	4,554	06 Dec 2022	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TXMD	Restricted Stock Units	Options Exercise	$0	-2,300	-100%	$0.000000^*	0	06 Dec 2022	Common Stock	2,300	$0.000000	Direct	F1, F4
transaction	TXMD	Restricted Stock Units	Options Exercise	$0	-380	-50%	$0.000000	380	06 Dec 2022	Common Stock	380	$0.000000	Direct	F1, F5
transaction	TXMD	Restricted Stock Units	Options Exercise	$0	-534	-33%	$0.000000	1,066	06 Dec 2022	Common Stock	534	$0.000000	Direct	F1, F6
transaction	TXMD	Restricted Stock Units	Options Exercise	$0	-262	-34%	$0.000000	519	06 Dec 2022	Common Stock	262	$0.000000	Direct	F1, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs).
F2	The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $4.76 and $5.29, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
F4	The RSUs vested in two equal installments on November 24, 2021 and November 24, 2022.
F5	The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.
F6	The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024.
F7	Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024.